← Leaderboards
Pamela N Munster
H. Lee Moffitt Cancer Ctr &Res Inst
$9,751,345
Attributed
$11,926,448
Total exposure
9
Grants
7
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.1M · FY2005–25$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$11,926,448 · 9
By mechanism
R01$10,324,920 · 5
R21$931,004 · 2
P30$670,524 · 2
Top collaborators
- Ralph Eugene Hurd5 shared
- Daniel B Vigneron5 shared
Others in their field
Top investigators on “Tumor”
- David Heimbrook · Leidos Biomedical Research, Inc.$636,492,067
- Leonard Freedman · Leidos Biomedical Research, Inc.$360,535,780
- Gregory H Reaman · National Childhood Cancer Foundation$208,276,509
- Richard K. Wilson · Washington University$203,917,615
- Norman Wolmark · Nsabp Foundation, Inc.$177,323,696
- Ronald T Mitsuyasu · University Of California Los Angeles$138,361,819
Research focus
TumorClinical TrialsTissuesResistanceTherapy ResistantTherapeutic TargetMalignant Breast NeoplasmMalignant NeoplasmsResearch PersonnelPharmaceutical PreparationsDesignTreatment ResponseSamplingEpigenetic ProcessBiological MarkersResponseIn VitroSignal TransductionLaboratoriesFutureIn VivoPre-ClinicalProgramsDose
Grant awards (36)
Integrating Epigenetic Modulation into DNA Damage Repair$658,646
R01 · FY2025 · CA · contact PI
Integrating Epigenetic Modulation into DNA Damage Repair$625,664
R01 · FY2024 · CA · contact PI
Integrating Epigenetic Modulation into DNA Damage Repair$642,872
R01 · FY2023 · CA · contact PI
Molecular Oncology Program$185,194
P30 · FY2023 · CA · contact PI
Integrating Epigenetic Modulation into DNA Damage Repair$656,890
R01 · FY2022 · CA · contact PI
Molecular Oncology Program$87,279
P30 · FY2022 · CA · contact PI
Developing silastic-silicone for the local delivery of hormonal therapy to prevent and treat breast cancer$362,569
R01 · FY2021 · CA · contact PI
Molecular Oncology Program$122,428
P30 · FY2021 · CA · contact PI
Developing silastic-silicone for the local delivery of hormonal therapy to prevent and treat breast cancer$362,569
R01 · FY2020 · CA · contact PI
Experimental Therapeutics Program$79,592
P30 · FY2020 · CA · contact PI
Developing silastic-silicone for the local delivery of hormonal therapy to prevent and treat breast cancer$351,691
R01 · FY2019 · CA · contact PI
Experimental Therapeutics Program$86,716
P30 · FY2019 · CA · contact PI
Translating HP 13C MRI as a Novel Paradigm for Assessing Drug Target Inhibition$657,821
R01 · FY2018 · CA
Developing silastic-silicone for the local delivery of hormonal therapy to prevent and treat breast cancer$362,569
R01 · FY2018 · CA · contact PI
Experimental Therapeutics Program$86,469
P30 · FY2018 · CA · contact PI
Experimental Therapeutics Program$10,743
P30 · FY2018 · CA · contact PI
Experimental Therapeutics Program$8,603
P30 · FY2018 · CA · contact PI
Experimental Therapeutics Program$3,500
P30 · FY2018 · CA · contact PI
Translating HP 13C MRI as a Novel Paradigm for Assessing Drug Target Inhibition$657,802
R01 · FY2017 · CA
Developing silastic-silicone for the local delivery of hormonal therapy to prevent and treat breast cancer$362,569
R01 · FY2017 · CA · contact PI
Translating HP 13C MRI as a Novel Paradigm for Assessing Drug Target Inhibition$655,718
R01 · FY2016 · CA
Translating HP 13C MRI as a Novel Paradigm for Assessing Drug Target Inhibition$641,305
R01 · FY2015 · CA
The role of HDAC2 in hormone therapy resistance$320,588
R01 · FY2015 · CA · contact PI
Translating HP 13C MRI as a Novel Paradigm for Assessing Drug Target Inhibition$650,008
R01 · FY2014 · CA
The role of HDAC2 in hormone therapy resistance$310,970
R01 · FY2014 · CA · contact PI
The role of HDAC2 in hormone therapy resistance$301,352
R01 · FY2013 · CA · contact PI
The role of HDAC2 in hormone therapy resistance$314,933
R01 · FY2012 · CA · contact PI
The role of HDAC2 in hormone therapy resistance$320,588
R01 · FY2011 · CA · contact PI
The Role of Selective HDAC Enzymes in Drug Sensitivity$271,618
R01 · FY2010 · CA · contact PI
The Role of Selective HDAC Enzymes in Drug Sensitivity$271,618
R01 · FY2009 · CA · contact PI
The Role of Selective HDAC Enzymes in Drug Sensitivity$271,618
R01 · FY2008 · CA · contact PI
The Role of Selective HDAC Enzymes in Drug Sensitivity$292,942
R01 · FY2007 · CA · contact PI
Potentiation of Topo Inhibitors by the HDACi, SAHA$210,155
R21 · FY2007 · CA · contact PI
Potentiation of Topo Inhibitors by the HDACi, SAHA$216,431
R21 · FY2006 · CA · contact PI
Potentiation of Topo Inhibitors by HDAC Inhibitors$252,209
R21 · FY2005 · CA
Potentiation of Topo Inhibitors by HDAC Inhibitors$252,209
R21 · FY2004 · CA